Sun Yat-sen University Advances Anlotinib in Phase 4 Head and Neck Cancer Trial (NCT04507035)
Sun Yat-sen University is conducting a Phase 4 clinical trial (NCT04507035) evaluating Anlotinib hydrochloride capsules combined with chemoradiotherapy for locally advanced head and neck cancer. This study, led by Principal Investigator Zhen-Wei Peng, targets improved survival and tumor regression in refractory cases. For procurement and business development, this highlights emerging treatment paradigms and potential market shifts in oncology.
Clinical Trial Overview: Anlotinib in Locally Advanced Head and Neck Cancer (NCT04507035)
Sun Yat-sen University, a prominent academic institution in China, has initiated a Phase 4 clinical trial (NCT04507035) to investigate the efficacy and safety of Anlotinib hydrochloride capsules in combination with chemoradiotherapy for patients with locally advanced head and neck malignant tumors. This study, officially titled 'Study on the Treatment of Refractory and Locally Advanced Head and Neck Malignant Tumor With Anlotinib Hydrochloride Capsules Combined With Chemoradiotherapy,' commenced patient recruitment in September 2020, with an estimated primary and overall completion date set for December 31, 2022. The Principal Investigator, Zhen-Wei Peng, is leading this single-group interventional study, which aims to enroll 30 patients. For procurement directors and business development executives, this Phase 4 trial signifies a strategic effort to expand the clinical utility of Anlotinib, a known anti-angiogenesis agent, into a challenging oncology indication. Monitoring the progress and outcomes of such late-stage trials is crucial for anticipating shifts in treatment guidelines and potential market demand for Anlotinib and its associated therapeutic components in the global head and neck cancer landscape. The focus on refractory cases suggests an unmet medical need that, if successfully addressed, could open new commercial avenues.
Therapeutic Approach and Patient Stratification for Anlotinib Combination
The trial's design centers on a combination therapy, utilizing Anlotinib hydrochloride capsules as a first-line treatment for two cycles, followed by an evaluation of tumor response. If tumor downgrading allows for surgery, resection will be performed. For inoperable cases, Anlotinib will be combined with radiotherapy and chemotherapy until the completion of radiotherapy. This adaptive treatment strategy aims to improve surgical resection rates or achieve local lesion control. The inclusion criteria for this study are highly specific, targeting male or female patients aged 18 to 75 years with a performance status (PS) score of ≤ 1, and an expected survival period exceeding three months. Pathologically diagnosed squamous cell carcinoma or non-squamous cell carcinoma of the head and neck, including sarcoma, adenoid cystic carcinoma, olfactory blastoma, and mucoepidermoid carcinoma, are eligible, provided the primary tumor is not curable by surgery. Patients must present with measurable lesions according to RECIST 1.1 criteria and have no prior anti-tumor or anti-angiogenesis therapy. Adequate liver, renal, and blood function are also mandatory. For supply chain VPs, these stringent patient criteria define a specific market segment, enabling more precise demand forecasting for Anlotinib hydrochloride capsules and associated chemotherapeutic agents. Understanding the target patient profile is essential for optimizing inventory management and distribution strategies.
Key Endpoints and Efficacy Evaluation in Head and Neck Oncology
The clinical trial's primary outcomes are the Objective Response Rate (ORR) and the Adverse Events Rate, both assessed at three months post-treatment. ORR, defined by complete and partial response rates, will be measured using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1, evaluated via computed tomography (CT) or magnetic resonance imaging (MRI). Adverse events will be monitored and graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Secondary outcomes extend to Progression-Free Survival (PFS) and Overall Survival (OS), both measured over a two-year timeframe. PFS is defined as the period from randomization until disease progression or death, while OS tracks survival until death from any cause. For regulatory affairs heads and business development executives, these endpoints are critical for evaluating the clinical benefit-risk profile of Anlotinib hydrochloride capsules in this challenging indication. Positive outcomes, particularly in ORR and survival metrics, could significantly bolster Anlotinib's market position and potentially lead to expanded indications or revised treatment guidelines. Conversely, an unfavorable safety profile could limit its adoption. The data generated from this Phase 4 study will be instrumental in shaping future commercial strategies and market access negotiations for Anlotinib in the global oncology sector.
Strategic Implications for Oncology Development and Regional Research
This Phase 4 study by Sun Yat-sen University underscores a growing trend in oncology research: the exploration of existing, approved drugs for new indications or in novel combination therapies to address unmet needs in advanced cancers. Anlotinib, an oral multi-target tyrosine kinase inhibitor, has demonstrated considerable effect in early-stage clinical exploration for locally advanced head and neck tumors, providing the rationale for this current investigation. The trial's focus on improving survival and achieving tumor degeneration in refractory cases aligns with global efforts to enhance outcomes for patients with aggressive malignancies. In the broader context of oncology development in China, this trial runs in parallel with other significant research initiatives, such as Peking University Cancer Hospital's multi-omics ESCC study (NCT07152535), indicating a robust and active research environment. For R&D departments and business development teams, this signifies the continued importance of academic-led research in validating and expanding therapeutic options. Successful results from Sun Yat-sen University could catalyze further investment in Anlotinib-based combination therapies and influence future pipeline development strategies, particularly for companies operating within or looking to enter the Chinese pharmaceutical market.
Procurement, Supply Chain, and Market Access Considerations for Anlotinib
The ongoing Phase 4 clinical trial for Anlotinib hydrochloride capsules by Sun Yat-sen University has direct implications for procurement, supply chain, and market access strategies. Should the trial demonstrate significant improvements in objective response rates and survival for locally advanced head and neck cancer, it could lead to increased demand for Anlotinib. Procurement directors must proactively assess the current supply chain resilience for Anlotinib and its active pharmaceutical ingredients (APIs), ensuring robust sourcing strategies to meet potential future demand spikes. Given Anlotinib's established presence, any expanded use would require careful planning to avoid supply disruptions. Furthermore, the combination with chemoradiotherapy means that demand for these co-administered agents could also be affected. Supply chain VPs should review logistics and distribution networks to accommodate potential shifts in volume and geographical reach. For market access teams, positive trial outcomes will provide crucial evidence for payer negotiations and formulary inclusions, especially in regions where head and neck cancer represents a significant burden. Business development executives should evaluate potential partnership opportunities with manufacturers of Anlotinib or related oncology therapies, anticipating a competitive landscape driven by new clinical evidence and evolving treatment paradigms.